Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

A real-world analysis of safety and outcomes with first line nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (NAVD) in patients with classic Hodgkin lymphoma (cHL) – a multicenter cohort study

Blood (2025) 146 (Supplement 1): 1841.

https://doi.org/10.1182/blood-2025-1841

Published: 2025

Journal Articles

Evaluation of real-world outcomes with zanubrutinib in patients with marginal zone lymphoma: Results from multicenter cohort study

Narendranath Epperla, Geoffrey Shouse, Jess Hatfield, Kanithra Sekaran, Yun Choi, Aishwarya Sannareddy, Bryce Bowler, Zain El-amir, Ly Do, Matthew Savas, Taylor Kujawa, Priyanka Pophali, Yasmin Karimi, Mengyang Di, Praveen Ramakrishnan Geethakumari, Yazeed Sawalha, Reem Karmali, Natalie Grover, Adam Olszewski

Blood (2025) 146 (Supplement 1): 4534.

https://doi.org/10.1182/blood-2025-4534

Published: 2025

Journal Articles

Evaluation of outcomes by line of therapy in marginal zone lymphoma: Real-world evidence from 10 US academic centers

Narendranath Epperla, John Sharp, Natalie Grover, Marcus Watkins, Reem Karmali, Pallawi Torka, Timothy Voorhees, Colin Thomas, Stefan Barta, Praveen Ramakrishnan Geethakumari, Nancy Bartlett, Geoffrey Shouse, Adam Olszewski

Blood (2025) 146 (Supplement 1): 4533.

https://doi.org/10.1182/blood-2025-4533

Published: 2025

Journal Articles

Consolidation (Cons) and maintenance (Maint) approaches in primary central nervous system lymphoma (PCNSL) after high-dose methotrexate induction in transplant-ineligible patients

Blood (2025) 146 (Supplement 1): 3671.

https://doi.org/10.1182/blood-2025-3671

Published: 2025

Journal Articles

Monte Carlo simulation of HLA-DQ heterodimers and their interactions to predict relapse and GVHD risk in cord blood transplantation

Julio Alvarenga Thiebaud, Alejandro Marinos Velarde, Stephen Chung, Clayton Jackson, Robert Collins, Vivian Irizarry Gatell, Yazan Madanat, Aimaz Afrough, Farrukh Awan, Praveen Ramakrishnan Geethakumari, Elif Yilmaz, Heather Wolfe, Larry Anderson, Adeel Khan, Yossel Alvarenga, Sanil Sansar, Chantalle Lacelle

Blood (2025) 146 (Supplement 1): 4307.

https://doi.org/10.1182/blood-2025-4307

Published: 2025

Journal Articles

Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world?

Blood (2025) 146 (Supplement 1): 3622.

https://doi.org/10.1182/blood-2025-3622

Published: 2025

Journal Articles

Single-Cell Insights into Cellular Heterogeneity and Immune Dynamics in Cutaneous T-Cell Lymphoma

Beth Childs, Eslam Elghonaimy, Praveen Ramakrishnan Geethakumari, Todd Aguilera, Heather W Goff

Blood (2024) 144 (Supplement 1): 6268.

https://doi.org/10.1182/blood-2024-206387

Published: 2024

Journal Articles

Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort

Juan Pablo Alderuccio, Jahanzaib Khwaja, Sunwoo Han, Paola Ghione, Imran A. Nizamuddin, Aditi Saha, Ning Dong, Yucai Wang, Hua-Jay J Cherng, Seda S. Tolu, Nina Wagner-Johnston, Adam J. Olszewski, Natalie Grover, Jean L. Koff, Amrita Desai, Praveen Ramakrishnan Geethakumari, Tamara K Moyo, Jose Sandoval-Sus, Narendranath Epperla, Danielle S Wallace, Manali Kamdar, Alexey Danilov, Han W. Tun, Javier Munoz, Mayur S. Narkhede, Joanna M. Rhodes, Anca Prica, Andrea Kuhnl, Adrian Maraj, Jessica Okosun, Jeffery Smith, Wendy Osborne, Victoria Calvert, Dima el-Sharkawi, Ammar Hilali, Graham P. Collins, Kim Linton, Nagah Elmusharaf, Anna Santarsieri, Farheen Karim, Thomas Ollila, Sarah Monick, Iris Margalit Trutzer, Nilanjan Ghosh, Jones Can, Amy Ayers, Jacopo Calabrese De Feo, John Sharp, Rachel Treitman, Avyakta Kallam, Izel Okcu, Vismay Deshani, Firas Baidoun, Chathuri Abeyakoon, William Hann, Aisling Barrett, Brad Kahl, Julio C. Chavez, Kate Cwynarski

Blood (2024) 144 (Supplement 1): 571.

https://doi.org/10.1182/blood-2024-199781

Published: 2024

Journal Articles

A Real-World (RW) Analysis of the Relationship between Epstein-Barr Virus (EBV) Positivity and Baseline Characteristics, Treatment Patterns and Clinical Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL)

Elif Yilmaz, Xiaoliang (Wendy) Wang, Niquelle Brown Wadé, Yu-Lun Liu, Praveen Ramakrishnan Geethakumari, Ahmed Sawas

Blood (2024) 144 (Supplement 1): 3719.

https://doi.org/10.1182/blood-2024-206358

Published: 2024

Journal Articles

Addition of Monoclonal Protein to MALT-IPI Improved Identification of MALT Patients at High Risk of Progression with Current First-Line Therapies

Narendranath Epperla, Natalie Grover, Pallawi Torka, Reem Karmali, Kaitlin Annunzio, Marcus P. Watkins, Andrea Carolina Anampa-Guzmán, Heather Reves, Montreh Tavakkoli, Beth Christian, Colin Thomas, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Geoffrey Shouse, Nancy L. Bartlett, Adam J. Olszewski

Blood (2024) 144 (Supplement 1): 398.

https://doi.org/10.1182/blood-2024-202697

Published: 2024

Journal Articles

Evaluation of Risk Factors for Histological Transformation in Patients with Marginal Zone Lymphoma (MZL): Results from a Multicenter Cohort Study

Blood (2024) 144 (Supplement 1): 2344.

https://doi.org/10.1182/blood-2024-202721

Published: 2024

Journal Articles

Enrollment in Clinical Trials Demonstrates Benefit for Low Income DLBCL Patients; A Retrospective National Cancer Database (NCDB) Analysis

William Schwartzman, Ang Gao, Chul Ahn, Heather R Wolfe, Praveen Ramakrishnan Geethakumari, Farrukh T. Awan, Elif Yilmaz

Blood (2024) 144 (Supplement 1): 5096.

https://doi.org/10.1182/blood-2024-210009

Published: 2024

Journal Articles

Ultra-Hypofractionated Involved Site Radiation Therapy (ISRT) As Salvage or Bridging Therapy in Aggressive Non-Hodgkin Lymphomas

Tanooha Veeramachaneni, Xingzhe Li, Neil Desai, Heather R Wolfe, Elif Yilmaz, Farrukh T. Awan, Robert H. Collins, Robert Timmerman, Praveen Ramakrishnan Geethakumari, Kiran Achut Kumar

Blood (2023) 142 (Supplement 1): 6283.

https://doi.org/10.1182/blood-2023-191089

Published: 2023

Journal Articles

Impact of Maintenance Rituximab Following First-Line Systemic Therapy on Outcomes in Patients with Marginal Zone Lymphoma: Real-World Evidence from 10 US Centers

Narendranath Epperla, Kaitlin Annunzio, Geoffrey P. Shouse, Natalie S. Grover, Pallawi Torka, Marcus P Watkins, Andrea Carolina Anampa-Guzmán, Timothy S. Oh, Heather Reves, Montreh Tavakkoli, Emily Hansinger, Beth Christian, Colin Thomas, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Reem Karmali, Nancy L. Bartlett, Adam J Olszewski

Blood (2023) 142 (Supplement 1): 5147.

https://doi.org/10.1182/blood-2023-185182

Published: 2023

Journal Articles

Impact of Large Cells and Ki-67% on Outcomes in Patients with Newly Diagnosed Marginal Zone Lymphoma - Results from a Multicenter Cohort Study

Narendranath Epperla, Natalie S. Grover, Kaitlin Annunzio, Marcus P Watkins, Pallawi Torka, Reem Karmali, Andrea Carolina Anampa-Guzmán, Timothy S. Oh, Heather Reves, Montreh Tavakkoli, Emily Hansinger, Beth Christian, Colin Thomas, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Nancy L. Bartlett, Geoffrey P. Shouse, Adam J Olszewski

Blood (2023) 142 (Supplement 1): 266.

https://doi.org/10.1182/blood-2023-185152

Published: 2023

Journal Articles

Allogeneic Stem Cell Transplant and CD30 Directed CART Cell Therapies Are Associated with Improved Survival in Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers

Blood (2023) 142 (Supplement 1): 900.

https://doi.org/10.1182/blood-2023-182385

Published: 2023

Journal Articles

Incidence of Invasive Fungal Infections in CAR T-Cell Therapy Recipients: A Single-Center Retrospective Analysis

Blood (2023) 142 (Supplement 1): 6921.

https://doi.org/10.1182/blood-2023-186596

Published: 2023

Journal Articles

Impact of Diagnosis to Treatment Interval on Outcomes in Patients with Newly Diagnosed Marginal Zone Lymphoma - a US Multisite Study

Blood (2023) 142 (Supplement 1): 5159.

https://doi.org/10.1182/blood-2023-185205

Published: 2023

Journal Articles

Outcomes in Patients with Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers

Blood (2023) 142 (Supplement 1): 3061.

https://doi.org/10.1182/blood-2023-181056

Published: 2023

Journal Articles

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

Blood (2023) 142 (Supplement 1): 355.

https://doi.org/10.1182/blood-2023-181181

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

A real-world analysis of safety and outcomes with first line nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (NAVD) in patients with classic Hodgkin lymphoma (cHL) – a multicenter cohort study

Evaluation of real-world outcomes with zanubrutinib in patients with marginal zone lymphoma: Results from multicenter cohort study

Evaluation of outcomes by line of therapy in marginal zone lymphoma: Real-world evidence from 10 US academic centers

Consolidation (Cons) and maintenance (Maint) approaches in primary central nervous system lymphoma (PCNSL) after high-dose methotrexate induction in transplant-ineligible patients

Monte Carlo simulation of HLA-DQ heterodimers and their interactions to predict relapse and GVHD risk in cord blood transplantation

Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world?

Single-Cell Insights into Cellular Heterogeneity and Immune Dynamics in Cutaneous T-Cell Lymphoma

Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort

A Real-World (RW) Analysis of the Relationship between Epstein-Barr Virus (EBV) Positivity and Baseline Characteristics, Treatment Patterns and Clinical Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL)

Addition of Monoclonal Protein to MALT-IPI Improved Identification of MALT Patients at High Risk of Progression with Current First-Line Therapies

Evaluation of Risk Factors for Histological Transformation in Patients with Marginal Zone Lymphoma (MZL): Results from a Multicenter Cohort Study

Enrollment in Clinical Trials Demonstrates Benefit for Low Income DLBCL Patients; A Retrospective National Cancer Database (NCDB) Analysis

Ultra-Hypofractionated Involved Site Radiation Therapy (ISRT) As Salvage or Bridging Therapy in Aggressive Non-Hodgkin Lymphomas

Impact of Maintenance Rituximab Following First-Line Systemic Therapy on Outcomes in Patients with Marginal Zone Lymphoma: Real-World Evidence from 10 US Centers

Impact of Large Cells and Ki-67% on Outcomes in Patients with Newly Diagnosed Marginal Zone Lymphoma - Results from a Multicenter Cohort Study

Allogeneic Stem Cell Transplant and CD30 Directed CART Cell Therapies Are Associated with Improved Survival in Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers

Incidence of Invasive Fungal Infections in CAR T-Cell Therapy Recipients: A Single-Center Retrospective Analysis

Impact of Diagnosis to Treatment Interval on Outcomes in Patients with Newly Diagnosed Marginal Zone Lymphoma - a US Multisite Study

Outcomes in Patients with Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only